As previously reported, BofA analyst Michael Ryskin upgraded Schrodinger (SDGR) to Buy from Neutral with an unchanged price target of $24. Recent quarterly results underscore resilience despite market noise, says the analyst, who sees a more favorable backdrop for Pharma and R&D spending while also citing Schrodinger’s strategic pivot toward its core strengths in Discovery and Software.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SDGR:
- Schrodinger upgraded to Buy from Neutral at BofA
- Cathie Wood’s ARK Investment buys 36.6K shares of Schrodinger today
- FDA guides on streamlined nonclinical monoclonal antibody safety studies
- Schrodinger management to meet with KeyBanc
- Private Markets: Microsoft, Nvidia to invest in Anthropic